News

ORION-8, the largest clinical trial completed to date with Leqvio, continues to support the consistent long-term efficacy, safety, and tolerability of Leqvio, with a total exposure of more than 8,500 patient-years during the trial’s...

Merck’s broad, global Phase 3 program for MK-0616 aims to enroll approximately 17,000 participants across the CORALreef Lipids, CORALreef HeFH and CORALreef Outcomes studies.

The portable Philips Ultrasound Compact System 5500 CV includes an AI-powered automation tool (the automated strain quantification) to assess the function of the heart’s left ventricle.

In this study, participants who said they had extreme pain after a heart attack were more than twice as likely to die during the study period compared to those who reported no pain.

In this project — funded under the NHLBI Catalyze Program — this new strategy will enable the suppression of white blood cell activation within atherosclerotic plaques beforehand by inhibiting the production of pro-inflammatory mediators...

A survey from the American Heart Association showed 75% of heart attack and stroke survivors reported having high cholesterol.

New research led by Penn State reveals that cardiovascular health measures, including heart rate and blood pressure, worsen over the course of the week when sleep is restricted to five hours per night, and attempting to catch up on sleep over...

Recor has reported positive outcomes in three independent, randomized, sham-controlled studies of the Paradise system in patients with mild-to-moderate and resistant hypertension.

This retrospective observational study is the first to investigate the development and risk factors associated with persistent high blood pressure in people with COVID-19 infection compared to influenza, a similar respiratory virus.

The research team was able to show that people with two loss of function CYP2C19 variants were more than three times more likely to have recurrent heart attacks, which may relate to clopidogrel treatment failure.